NasdaqGS - Nasdaq Real Time Price ? USD Indivior PLC (INDV) Follow Compare 8.27 -0.29 (-3.39%) At close: October 21 at 4:00 PM EDT 8.27 0.00 (0.00%) After hours: October 21 at 5:32 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Two Seas Capital LP Increases Stake in Indivior PLC On October 15, 2024, Two Seas Capital LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 400,001 shares of Indivior PLC (NASDAQ:INDV), a specialty drug manufacturing company. This transaction has increased the firm's total holdings in Indivior to 13,030,027 shares, marking a substantial influence on its investment strategy. Two Seas Capital LP (Trades, Portfolio), based at 1 Read Court, New York, NY 10580, is a prominent investment firm known for its strategic positions in the healthcare and utilities sectors. GuruFocus.com ? 4 days ago INDV -3.39% Indivior price target lowered to $16 from $20 at Craig-Hallum Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointing update.” The company lowering FY24 net revenue guidance was “entirely driven by worsening fundamentals for Sublocade,” notes the analyst, who calls Sublocade “the chief value driver for Indivior.” There is hope f TipRanks ? 9 days ago INDV -3.39% Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... Indivior PLC (INDV) outlines strategic initiatives to bolster SUBLOCADE's market position amidst increased competition and evolving market dynamics. GuruFocus.com ? 10 days ago INDV -3.39% Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion – $1.215 billion. In particular, the company now expects lower-than-antic Benzinga ? 11 days ago INDV -3.39% Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook MT Newswires ? 11 days ago INDV -3.39% Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance. PR Newswire ? 11 days ago INDV -3.39% Indivior's SUBLOCADE? Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE? (buprenorphine extended-release) injection submitted by Indivior, Inc. has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) action date for this submission is set for February 7, 2025. PR Newswire ? 14 days ago INDV -3.39% Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... Series A financing, milestone payments, and strategic partnerships mark a pivotal quarter for Addex Therapeutics Ltd (ADXN). GuruFocus.com ? 20 days ago INDV -3.39% Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 26 days ago RIGL INDV -3.39% Top 3 Health Care Stocks That May Explode This Month The most oversold stocks in the health care sector present an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When ... Benzinga ? 28 days ago MRNA INDV -3.39% PGNY Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma's announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. PR Newswire ? last month INDV -3.39% Addex Stock Soars on Crucial Update From Indivior Research Deal ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies. Zacks ? last month INDV -3.39% FULC Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro. Addex Therapeutics and Indivior PLC (NASDAQ:INDV) announced that they have selected clinical candidates from their GABAB-positive allosteric modulator (PAM) research collaboration. Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected Benzinga ? last month INDV -3.39% JNJ Indivior Announces BARDA's First Order of OPVEE? to Combat Opioids and Aid in National Preparedness Indivior PLC (LSE/Nasdaq: INDV) today announced the first order of OPVEE? (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support its ongoing national preparedness efforts and help save lives during potential synthetic opioid overdose emergencies. OPVEE is the first and only nasal rescue medicine specifically indicated for PR Newswire ? last month INDV -3.39% Indivior reaches $86 million opioid settlement with 16 US states NEW YORK (Reuters) -Indivior reached an $86 million settlement with 16 U.S. states over the drug manufacturer's alleged role in spreading opioid addiction across the United States, New York Attorney General Letitia James said on Friday. James said the settlement in principle concerned Indivior's manufacture of buprenorphine-based products meant to treat opioid abuse, but which allegedly can fuel addiction if misused. Reuters ? 2 months ago INDV -3.39% Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates Indivior (INDV) delivered earnings and revenue surprises of 10% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago INDV -3.39% Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame Indivior PLC (Nasdaq/LSE: INDV) ("Indivior" or the "Company"), a leading addiction treatment company, today announced that its Board of Directors has approved a new share repurchase program under which the Company will commence repurchasing Indivior's ordinary shares of $0.50 each (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "New Program"). The New Program will be carried out on an accelerated basis and is expected to be completed over the next six months, subje PR Newswire ? 2 months ago INDV -3.39% Indivior Announces Q2 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. PR Newswire ? 2 months ago INDV -3.39% Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 3 months ago STVN -0.66% INDV -3.39% Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 3 months ago INDV -3.39% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is FTSE 100 Return INDV FTSE 100 YTD -45.84% +7.57% 1-Year -55.54% +12.38% 3-Year +160.88% +15.16%
